Work

BOP2-FE: Bayesian optimal phase II design with futility and efficacy-stopping boundaries

Year: 2025

Type: article

Source: Journal of Biopharmaceutical Statistics

DOI: 10.1080/10543406.2025.2558142

Authors: Xinling Xu, Atsuki Hashimoto, Belay B Yimer, Kentaro Takeda

Institutions: Astellas Pharma (United States), Astellas Pharma (United Kingdom)

Language: English

Topic: Statistical Methods in Clinical Trials

Subfield: Statistics and Probability

Field: Mathematics

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414281878

FWCI: 1.743

Cites: 23

Cited by: 1

Related to: